Conestat alfa
- Generic Name
- Conestat alfa
- Brand Names
- Ruconest
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 80295-38-1
- Unique Ingredient Identifier
- 5QS67N4551
- Background
C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. It does this through inhibition of several target proteases within ...
- Indication
For the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults.
- Associated Conditions
- Acute attacks of hereditary angioedema
- Associated Therapies
- -
Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 24
- Registration Number
- NCT06679426
Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 80
- Registration Number
- NCT04414631
- Locations
- 🇲🇽
Hospital Universitario "Dr. José Eleiterio González", Colinia Mitras Centro, Monterey, Nuevo Leon Mexico, Mexico
🇨ðŸ‡University Hospital Basel, Division of Internal Medicine, Basel, Switzerland
🇨ðŸ‡Stadtspital Triemli, Departement Innere Medizin, Zürich, Switzerland
Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 80
- Registration Number
- NCT02869347
- Locations
- 🇨ðŸ‡
University Hospital Basel, Basel, BS, Switzerland
A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration
- Conditions
- Interventions
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 25
- Registration Number
- NCT00851409
- Locations
- 🇷🇴
Emergency County Hospital, Internal Medicin Clinica, Allergology-Immunology Department, Târgu-Mureş, Romania
🇳🇱For information on sites, please contact Pharming Technologies, Leiden, Netherlands
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
- Conditions
- Interventions
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 75
- Registration Number
- NCT00262301
- Locations
- 🇷🇴
Emergency County Hospital, Internal Medicin Clinica, Allergology-Immunology Department, Tirgu Mures, Romania
🇳🇱For information on sites, please contact Pharming Medical Affairs Deparment, Leiden, Netherlands
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
- Conditions
- Interventions
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 77
- Registration Number
- NCT00225147
- Locations
- 🇳🇱
For information on sites please contact Pharming Medical Affairs Department, Leiden, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.